Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 3, Number 1-2, April 2013, pages 7-15


Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

Tables

Table 1. Changes in IGF-1 Levels (Mean ± SEM) After 12 Weeks of Treatment With AOD9604
 
Treatment groupIGF-1 changes from baselineP-value (mmol/L) compared to placebo
Placebo0.12 (0.56)
1 mg AOD9604-0.12 (0.58)1.00
5 mg AOD9604-0.18 (0.55)0.99
10 mg AOD96040.41 (0.52)0.99
20 mg AOD96041.28 (0.53)0.38
30 mg AOD96040.63 (0.59)0.95

 

Table 2. Summary of Serious Adverse Events (SEA) Reported
 
Placebo (n =125)AOD9604
0.25 mg (n =127)
AOD9604
0.5 mg (n = 125)
AOD9604
1 mg (n =125)
Total (n =502)
Any serious adverse event831618 (3.6%)